

Certificate of Immunization P.1

University Student Health Services

Monroe Park Campus

1300 West Broad Street, Suite 2200 Box 842022 Richmond, VA 23284-2022 PH: 804-827-8047 Fax: 804-828-1093 https://health.students.vcu.edu/ https://health.students.vcu.edu/

Health Sciences Campus 1000 E. Marshall St., Room 305 Richmond, VA 23298-0201 PH: 804-828-9220 Fax: 804-828-3181

All full-time students are required by the Code of Virginia (Section 23.1-800) to provide documentation of their immunizations by a licensed health professional. If you are unable to provide appropriate documentation, vaccines may be repeated. A registration hold for the upcoming semester will be placed if all required immunizations are not up-to-date.

Name	Last First		Middl	e Initial	
Date of Birth: Student V#:					
VCU E	Email: VCU Address:				
Were	you born in the U.S.A.? Yes No If no, country of birth:		Country	of Residence	:
lmmu	nization	Dose 1 (MM/DD/YY)	Dose 2 (MM/DD/YY)	Dose 3 (MM/DD/YY)	Dose 4 (MM/DD/YY)
	REQUIRED IMMUNIZA	TIONS			
or ††	Hepatitis B (3 dose series or TWINRIX (circle one) OR 2 dose HEPLISAV-B ™)			X	X
t	Measles, Mumps, Rubella (MMR) After 1st birthday and ≥ 28 days apart			X	X
tt	Meningococcal Vaccine One dose required after 16th birthday		X	X	X
	Polio (Required for 18 and under OR from countries of high risk including Afghanistan and Pakistan)				
	Tdap or Td (circle one) Current dose within 10 years		X	X	X
	Tuberculosis (TB) Screening/Testing (All part and full time student form on page 4 OR complete and submit the electronic form available.	•	•		screening
	OPTIONAL IMMUNIZA	rions			
	Diphtheria, Pertussis, Tetanus (DPT)	# doses rec:	# doses rec: last dose date:		
	Hepatitis A			X	\times
	HPV: HPV4 HPV9				X
	Meningococcal Group B (MenB does not meet the Meningococcal Vaccine requirement)				X
	Varicella (Chicken Pox) After 1st birthday and ≥ 28 days apart OR date of disease (Day/Month/Year) (/ /)			X	X
	COVID 19: Updated Annually Circle One: Pfizer Moderna		\times	X	\times
	Influenza: Updated Annually		\times	\times	\times
	atives [†] Attach lab result confirming serological immunity ^{††} Sign Wai onic form available through the Web Portal.	ver : Complet	e the waiver or	n page 3 or sub	mit the

Date

Healthcare Provider or Health Department Signature

Phone



University Student Health Services

Monroe Park Campus

1300 West Broad Street, Suite 2200 Box 842022 Richmond, VA 23284-2022 PH: 804-827-8047 Fax: 804-828-1093 https://health.students.vcu.edu/

Health Sciences Campus

1000 E. Marshall St., Room 305 Richmond, VA 23298-0201 PH: 804-828-9220 Fax: 804-828-3181 https://health.students.vcu.edu/

Nam	ne: Date of Birth:	Stud	lent V#		
	Additional Vaccination Requirements Generally I	Required by Clinical Trai	ning Sites		
	use verify requirements with your clinical site. For up-to-date vaccine info https://www.cdc.gov/vaccines/adults/rec-vac/index.html#other. Click c				
	COVID 19: Updated Annually	Circle One:	Pfizer Moderna	MM/	DD/YY
	Influenza: Update annually			MM/	DD/YY
†	Varicella (Chicken Pox) Two doses after 1st birthday and ≥ 28 days apart OR copy quantitative lab report. (Titer is not required if doses of vaccine spaced		Immunity with a	Dose 1	Dose 2
†	Hepatitis B Titer Serological confirmation of immunity with copy of quantita	tive lab report		1	1
	Alternatives† Attach lab result confirming serological immunity				
	Tuberculosis(TB)Testing Undergo two-step Tuberculin skin test (TST) OR have	e 1 Interferon Gamma Relea	ase Assay Test (IGRA)	
	Tests must be done at least 7 days apart but no more than 30 days k repeated. Test 1: Date Placed:Date ReadResult(mm). Test 2: Date Placed:Date ReadResult(mm). B. IGRA (QFT Gold or T-Spot) Date Performed:P Indeterminate or borderline results are not acceptable. Repeat test	positivenegative	/enegative /enegative *Attach copy of la		
	C. History of a prior Positive TST or IGRA (QFT Gold or T-Spot) *Please complete page 5 TB symptom survey. *Chest X-Ray must be after positive TST or IGRA and within 6 month				
—— Hea	althcare Provider or Health Department Signature	 Date	Phor	 ne	



Waivers, Consent, and Exemptions

University Student Health Services

Monroe Park Campus

1300 West Broad Street, Suite 2200 Box 842022 Richmond, VA 23284-2022 PH: 804-827-8047 Fax: 804-828-1093

https://health.students.vcu.edu/

Health Sciences Campus

1000 E. Marshall St., Room 305 Richmond, VA 23298-0201 PH: 804-828-9220 Fax: 804-828-3181 https://health.students.vcu.edu/

Name:	Date of Bi	irth:	Student V#			
Hepatitis B Vaccine Waiver						
	have read and reviewed information on the risk associated with hepatitis B disease, availability and effectiveness of any vaccine against hepatitis B disease and I choose not to be vaccinated against hepatitis B disease.					
Signature of Student or Paren	t/Legal Guardian	Da	ate			
Meningococcal Vaccine Waive	er er					
	rmation on the risk associated w al disease and I choose not to be		e, availability and effectiveness of any ngococcal disease			
Signature of Student or Paren	t/Legal Guardian	Da	ate			
The law requires that parental form should be signed by the	parents so that medical care ma cians, and staff nurses of VCU S	er to provide medical or su ay be carried out promptly	urgical care to minors. This consent without unnecessary delays. I hereby examine, interview, test and, if			
Signature of Student or Paren	t/Legal Guardian	Da	ate			
Medical Exemption						
	ginia § 22.1-271.2, C (ii), I certify nealth. The vaccine(s) is (are) spe		vaccine(s) designated below would be because			
			ps:[]; HBV:[]; Varicella:[]; Influenza [] to preclude immunizations until:			
Date (MM/DD/YY):						
Signature of Medical Provider	/Health Department Official	D	ate			

Religious Exemption

Any student who objects on the grounds that administration of immunizing agents conflicts with his or her religious tenets or practices shall be exempt from the immunization requirements unless an emergency or epidemic of disease has been declared by the Board of Health. An affidavit of religious exemption must be submitted on a Certificate of Religious Exemption (Form CRE-1) found online by visiting health.students.vcu.edu, under the Immunizations tab, and then under the Forms & Documents page.



Virginia Tuberculosis Risk Assessment

University Student Health Services

Monroe Park Campus 1300 West Broad Street, Suite 2200

Box 842022 Richmond, VA 23284-2022 PH: 804-827-8047 Fax: 804-828-1093

https://health.students.vcu.edu/

Health Sciences Campus

1000 E. Marshall St., Room 305 Richmond, VA 23298-0201 PH: 804-828-9220 Fax: 804-828-3181 https://health.students.vcu.edu/

irist screen for TB Symptoms (check all that apply): NoneCough (3 weeks or more)HemoptysisFeverWeight LossPoor AppetiteNight SweatsFa If present, evaluate for active TB disease. If none, complete the risk factor portion below. Have you had a prior positive TB test (PPD or IGRA)? YesNo *If yes, please complete the TB symptom survey form on page 5 and sign below. Use this tool to identify asymptomatic individuals 6 years and older for latent TB infection (LTBI) testing. Re-testing should only be done in persons who previously tested negative and have new risk factors since the last assessment. A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended from the past year (must be completed in the US) if any of the risks below are che if TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, inject	ame:	Date of Birth:	Student V#
Have you had a prior positive TB disease. If none, complete the risk factor portion below. Have you had a prior positive TB test (PPD or IGRA)? YesNo *If yes, please complete the TB symptom survey form on page 5 and sign below. Use this tool to identify asymptomatic individuals 6 years and older for latent TB infection (LTBI) testing. • Re-testing should only be done in persons who previously tested negative and have new risk factors since the last assessment. • A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. • Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended from the past year (must be completed in the US) if any of the risks below are che If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. ■ Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months • Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. • IGRA is preferred over TST for non-US-born persons ≥ 2 years old. • Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/d		eck all that apply):	
Have you had a prior positive TB test (PPD or IGRA)? YesNo *If yes, please complete the TB symptom survey form on page 5 and sign below. Use this tool to identify asymptomatic individuals 6 years and older for latent TB infection (LTBI) testing. Re-testing should only be done in persons who previously tested negative and have new risk factors since the last assessment. A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended from the past year (must be completed in the US) if any of the risks below are che If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation.	NoneCough (3 weeks or mo	re)HemoptysisFeverWeight Los	ssPoor AppetiteNight SweatsFatigue
*If yes, please complete the TB symptom survey form on page 5 and sign below. Use this tool to identify asymptomatic individuals 6 years and older for latent TB infection (LTBI) testing. • Re-testing should only be done in persons who previously tested negative and have new risk factors since the last assessment. • A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. • Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended from the past year (must be completed in the US) if any of the risks below are che If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. ■ Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months ■ Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. ■ IGRA is preferred over TST for non-US-born persons ≥ 2 years old. ■ Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. ■ Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. ■ Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication ■ Close contact to someone with infectious TB disease at any time ■ None, no TB testing indicate	If present, evaluate for active TB di	sease. If none, complete the risk factor po	ortion below.
 Re-testing should only be done in persons who previously tested negative and have new risk factors since the last assessment. A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended from the past year (must be completed in the US) if any of the risks below are che If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time. 			below.
 A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended from the past year (must be completed in the US) if any of the risks below are che lif TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time. 	Use this tool to identify asympt	omatic individuals 6 years and older f	or latent TB infection (LTBI) testing.
 A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended from the past year (must be completed in the US) if any of the risks below are che If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time. 		in persons who previously tested negative	e and have new risk factors since the last
TB infection testing is recommended from the past year (must be completed in the US) if any of the risks below are che If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time.	A negative Tuberculin Skin Test	-	
If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time.	Check appropriate risk factors bel	ow.	
 Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time. 	TB infection testing is recommend	led from the past year (must be completed	d in the US) if any of the risks below are checked.
 Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time. 	If TB infection result is positive an	d active TB disease is ruled out, TB infectio	on treatment is recommended.
 European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time. 	Birth, travel, or residence	in a country with an elevated TB rate	≥ 3 months
 IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time. 	 Includes countries other 	er than the United States (US) , Canada, Aus	stralia, New Zealand, or Western and North
 Clinicians may make individual decisions based on the information supplied during the evaluation. Individual have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time. 	•	TOT (JIC)	
have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be cons for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time.			
for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time.	1		· · · · · · · · · · · · · · · · · · ·
Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal for on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time.		·	•
or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time.	Medical conditions increa	sing risk for progression to TB disease	3
HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time.			
steroids (equivalent of prednisone ≥ 15 mg/day for ≥ month) or other immunosuppressive medication Close contact to someone with infectious TB disease at any time None, no TB testing indicated at this time.	Immunosuppression, curr	ent or planned	
None, no TB testing indicated at this time.			
	Close contact to someone	with infectious TB disease at any time	
Signature of Student or Parent/Legal Guardian Date	None, no TB testing indica	ted at this time.	
Signature of Student or Parent/Legal Guardian Date			
Signature of Student or Parent/Legal Guardian Date			
	Signature of Student or Parent/Leg	gal Guardian [Date

Once your form is reviewed, you may be contacted for more information if indicated.

Provider Signature (if indicated)

Date



Tuberculosis Symptom Survey

University Student Health Services

Monroe Park Campus

1300 West Broad Street, Suite 2200 Box 842022 Richmond, VA 23284-2022

PH: 804-827-8047 Fax: 804-828-1093 https://health.students.vcu.edu/

Health Sciences Campus

1000 E. Marshall St., Room 305 Richmond, VA 23298-0201 PH: 804-828-9220 Fax: 804-828-3181 https://health.students.vcu.edu/

Name:	Dat	te of Birth:	Student V#
Complete IF history of POSITIVE *Positive TB Test Date:			GRA (T-Spot or QFT)**OR Positive IGRA Date
*Enclose copy of positive TB test do			se copy of report; IGRA + Quantiferon Gold or T-Spot
Last Chest X-Ray Date:	Result:		Enclose copy of latest chest x-ray report
Have you taken medication for a TB			
			 Date Completed:
INHRifar			HP (12 week DOT)3HR
Are you interested in discussing late	nt TR infecti	on treatment w	vith a clinician? Yes No
Do you currently have any of the following t			
Cough lasting more than three weeks?	Yes	No	
Unexplained weight loss?	Yes	No	
Loss of appetite?	Yes	No	
Unexplained fatigue?	Yes	No	
Fever and/or night sweats?	Yes	No	
Blood tinged sputum production?	Yes	No	
If "Yes" to any questions, please exp	I lain further, i	I including date	of onset and any treatment
I am aware that the six symptoms list should promptly report to my health			s/symptoms of active tuberculosis disease that I
Signature of Student			Date
For Healthcare Provider Use: I have reviewed the above informat LTBI treatment discussed:	_		ent's information as indicated above.
Healthcare Provider Signature		Date	Phone